期刊文献+

三种血管紧张素Ⅱ受体拮抗剂类药物降压治疗的成本-效果分析 被引量:4

下载PDF
导出
摘要 目的分析3种血管紧张素Ⅱ受体拮抗剂(ARB)类药物降压治疗的成本-效果。方法选择2010—2011年我院内科门诊就诊的原发性高血压患者158例,将其随机分成缬沙坦组、替米沙坦组和氯沙坦钾组,分别给予缬沙坦80 mg/d、替米沙坦80 mg/d、氯沙坦钾50 mg/d,均为晨起口服,连续观察8周。统计3组治疗效果、不良反应情况,并进行成本-效果分析。结果治疗8周后,缬沙坦组总有效率为89.1%(49/55),替米沙坦组总有效率为92.3%(48/52),氯沙坦钾组总有效率为88.2%(45/51),3组疗效比较,差异无统计学意义(P>0.05);3组不良反应均轻微;替米沙坦组的成本-效果比小于缬沙坦组和氯沙坦钾组(P<0.05)。结论应用替米沙坦进行降压治疗是比较经济合理的,且患者依从性好。
作者 许凯
出处 《实用心脑肺血管病杂志》 2014年第1期81-82,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献7

二级参考文献121

  • 1李爱民,何作云,覃军,周小波,耿建萌.氯沙坦干预早期动脉粥样硬化家兔内膜增生的相关因素[J].中国临床康复,2004,8(18):3491-3493. 被引量:4
  • 2景涛,何国祥,刘建平,王海东,吴昊,王耿,冉擘力.坎地沙坦,PD123319及金雀异黄素对大鼠血管平滑肌细胞迁移影响[J].中国新药与临床杂志,2005,24(1):35-38. 被引量:3
  • 3MEYER J. Age: 2000. Census 2000 Brief[C]. Washington,DC: US Dept of Commerce, Economics and Statistics Administration, US Census Bureau,2001.
  • 4FIELDS LE, BURT VL, CUTLER JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide [ J ]. Hypertension, 2004,44 ( 4 ) : 398 - 404.
  • 5LLOYD-JONES DM, EVANS JC, LEVY D. Hypertension in adults across tile age spectrum: current outcomes and control in the community [J].JAMA ,2005,294 (4) :466 - 472.
  • 6WASSERTHEIL-SMOLLER S, ANDERSON G, PSATY BM, et al. Hypertension and ils treatment in postmenopausal women: baseline data from the Women's Health Initiative [ J ]. Itypertension,2000,36(5) :780 - 789.
  • 7HANSSON L, ZANCHETTI A, CARRUTHERS SG, et al. Effects of intensive hlood-pressure lowering and low-duse aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment(HOT) randomized trial[J].Lancet, 1998, 351 (9118) :1755 - 1762.
  • 8ALLHAT Collaborative Researeh Group. Major outcomes in highrisk hyperteusive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)[J].JAMA,2002,288(23):2981 -2997.
  • 9DAHLOF B, DEVEREUX RB, KJELDSEN SE, et al. For the LIFE Study Group. Cardiovascular morbidity and mortality in tile Losartan Intervention For Endpoint reduction in hypertension study( LIFE): a randomized trial against atenolol[J]. Lancet, 2002,359(9311 ) :995 - 1003.
  • 10JULIUS S, KJELDSEN SE, WEBER M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial[ J ]. Lancet,2004,363 ( 9426 ) :2022 - 2031.

共引文献97

同被引文献41

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部